BioSpace News Archive

When the cold weather arrives, so does lowered humidity, making dry and itchy skin an uncomfortable but customary part of the winter season as the body naturally reacts to the abrupt temperature changes.

Amgen (NASDAQ: AMGN) today announced results from the Phase 2 cohort of the CodeBreaK 100 clinical study evaluating investigational sotorasib (AMG 510) in 126 patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC)

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced its third quarter financial results for the quarter ended September 30, 2020.

The oxygen cylinders and concentrators market is projected to record tremendous growth on account of rising elderly population base that is mostly prone to chronic respiratory diseases like asthma, pulmonary, and COPD.

The pH meters market growth is a result of the growing incidences of food adulteration in developing as well as developed countries.

Growing cases of influenza and chronic disorders such as diabetes and cardiovascular diseases will fuel rapid influenza diagnostic tests (RIDT) market share in the coming years.

A look at the latest advancements in the global rat model market unveils a study that examined the possible therapeutic methods for humans dealing with opioid addiction.

Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced that it has received CE Mark approval for updated labeling of the Company’s biological CanGaroo® Envelope to allow for the addition of the antibiotic gentamicin. While the indications of the CanGaroo Envelope remain unchanged

Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of an underwritten public offering of 16,428,571 shares of its common stock, offered at a price of $1.75 to the public,

Sandoz, a global leader in generic and biosimilar medicines, today announced the US launch of generic Icatibant injection pre-filled syringe to treat acute attacks of rare disease hereditary angioedema (HAE) in adults 18 years and older.1 It is available immediately for US patients.